Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Edetate→

Edetate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
64-02-8
Molecular formula
C10H12N2Na4O8
Molecular weight
380.17 g/mol
Drug class
EDTA chelating agentexact salt form must be confirmed (e.g. calcium disodium edetate versus disodium edetate)
Mechanism of action
Edetate forms stable coordination complexes with divalent and trivalent metal ions. The clinical behaviour and indication depend materially on the EDTA salt: calcium disodium edetate is used for lead chelation, whereas disodium edetate has a different calcium-binding profile and can cause severe hypocalcaemia.

Sources: US DailyMed — Edetate calcium disodium injection (lead chelation) · NCBI Bookshelf — EDTA pharmacology and salt-form distinctions · PubChem — Edetate disodium (distinct salt form) · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

EDTA chelating agent; exact salt form must be confirmed (e.g. calcium disodium edetate versus disodium edetate)

Mechanism of action

Edetate forms stable coordination complexes with divalent and trivalent metal ions. The clinical behaviour and indication depend materially on the EDTA salt: calcium disodium edetate is used for lead chelation, whereas disodium edetate has a different calcium-binding profile and can cause severe hypocalcaemia.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Edetate Environmental Risk Assessment (ERA) (the Edetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.